Publicaciones en colaboración con investigadores/as de Complejo Hospitalario Universitario de Albacete (11)

2022

  1. ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology

    Cancers, Vol. 14, Núm. 14

2020

  1. Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer

    Cancer Letters, Vol. 491, pp. 50-59

2019

  1. A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors

    Frontiers in Immunology, Vol. 10

  2. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 38, Núm. 1

2016

  1. Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies

    Oncotarget, Vol. 7, Núm. 29, pp. 45042-45051

  2. Targeting the EGF/HER ligand-receptor system in cancer

    Current Pharmaceutical Design, Vol. 22, Núm. 39, pp. 5887-5898

2014

  1. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer

    Oncogene, Vol. 33, Núm. 2, pp. 148-156

2013

  1. ERK5/BMK1 is a novel target of the tumor suppressor VHL: Implication in clear cell renal carcinoma

    Neoplasia (United States), Vol. 15, Núm. 6, pp. 649-659

2009

  1. Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as potential therapeutic target

    PLoS ONE, Vol. 4, Núm. 5

2008

  1. Neuregulins and cancer

    Clinical Cancer Research, Vol. 14, Núm. 11, pp. 3237-3241

  2. Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells

    Annals of Oncology, Vol. 19, Núm. 11, pp. 1860-1869